Lebwohl David 4

4 · Intellia Therapeutics, Inc. · Filed Mar 3, 2022

Form 4

Period: 2022-01-01

EVP, Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2022-01-01+3,187→ 11,973 total
Award
Common Stock
2022-03-01+13,816→ 24,738 total
Award
Stock Option (right to buy)
2022-03-01+13,816→ 13,816 total
Exercise: $79.85Exp: 2032-02-28→ Common Stock (13,816 underlying)
Sale
Common Stock
2022-01-01$112.24/sh−1,051$117,964→ 10,922 total
Exercise/Conversion
Restricted Stock Unit
2022-01-01−3,187→ 9,563 total
From: 2022-01-01Exp: 2031-03-02→ Common Stock (3,187 underlying)

Footnotes (6)

[F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
[F2]Includes 72 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2021.
[F3]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
[F4]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
[F5]On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
[F6]This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Documents

1 file